Crimean-Congo haemorrhagic fever (CCHF) constitutes a public health threat because of its epidemic potential, its high case fatality ratio (4-40%), its potential for nosocomial outbreaks and the lack of effective treatment and prophylaxis. CCHF is endemic in all of Africa, Southern Europe, the Middle East and in Asia. In 2016, CCHF was listed as a WHO priority pathogen for which urgent research and development (R&D) is needed. The need for safe and effective CCHF vaccines and treatments was underscored in the CCHF roadmap for product R&D aiming to prevent or mitigate CCHF disease by 2030.
On 31 October 2019, WHO convened members of the R&D Blueprint working group on clinical trial design with CCHF experts as well as national representatives from affected countries to discuss the science of vaccine and treatment evaluation for CCHF and to agree on principles and approaches to determine whether or not CCHF vaccines and therapeutics are safe and effective. Deliberations were informed by key clinical and epidemiological considerations, also recognizing the critical knowledge gaps that well-designed clinical and epidemiological studies could help address to better inform the development of CCHF therapeutics and vaccines.
Download the agenda →
Download the list of participants →
Download the meeting report →